Colorectal Cancer Liver Metastasis

Evolving Paradigms and Future Directions

Luai R. Zarour, Sudarshan Anand, Kevin Billingsley, William H. Bisson, Andrea Cercek, Michael F. Clarke, Lisa Coussens, Charles E. Gast, Cristina B. Geltzeiler, Lissi Hansen, Katherine A. Kelley, Charles Lopez, Shushan R. Rana, Rebecca Ruhl, Vassiliki Tsikitis, Gina Vaccaro, Melissa Wong, Skye Mayo

Research output: Contribution to journalReview article

33 Citations (Scopus)

Abstract

In patients with colorectal cancer (CRC) that metastasizes to the liver, there are several key goals for improving outcomes including early detection, effective prognostic indicators of treatment response, and accurate identification of patients at high risk for recurrence. Although new therapeutic regimens developed over the past decade have increased survival, there is substantial room for improvement in selecting targeted treatment regimens for the patients who will derive the most benefit. Recently, there have been exciting developments in identifying high-risk patient cohorts, refinements in the understanding of systemic vs localized drug delivery to metastatic niches, liquid biomarker development, and dramatic advances in tumor immune therapy, all of which promise new and innovative approaches to tackling the problem of detecting and treating the metastatic spread of CRC to the liver. Our multidisciplinary group held a state-of-the-science symposium this past year to review advances in this rapidly evolving field. Herein, we present a discussion around the issues facing treatment of patients with CRC liver metastases, including the relationship of discrete gene signatures with prognosis. We also discuss the latest advances to maximize regional and systemic therapies aimed at decreasing intrahepatic recurrence, review recent insights into the tumor microenvironment, and summarize advances in noninvasive multimodal biomarkers for early detection of primary and recurrent disease. As we continue to advance clinically and technologically in the field of colorectal tumor biology, our goal should be continued refinement of predictive and prognostic studies to decrease recurrence after curative resection and minimize treatment toxicity to patients through a tailored multidisciplinary approach to cancer care.

Original languageEnglish (US)
Pages (from-to)163-173
Number of pages11
JournalCMGH Cellular and Molecular Gastroenterology and Hepatology
Volume3
Issue number2
DOIs
StatePublished - Mar 1 2017

Fingerprint

Liver Neoplasms
Colorectal Neoplasms
Neoplasm Metastasis
Recurrence
Therapeutics
Biomarkers
Tumor Microenvironment
Direction compound
Neoplasms
Survival
Pharmaceutical Preparations

Keywords

  • Biomarkers
  • Colorectal Cancer Liver Metastasis
  • Hepatic Arterial Infusion
  • High-Risk Colorectal Cancer
  • Recurrence

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Colorectal Cancer Liver Metastasis : Evolving Paradigms and Future Directions. / Zarour, Luai R.; Anand, Sudarshan; Billingsley, Kevin; Bisson, William H.; Cercek, Andrea; Clarke, Michael F.; Coussens, Lisa; Gast, Charles E.; Geltzeiler, Cristina B.; Hansen, Lissi; Kelley, Katherine A.; Lopez, Charles; Rana, Shushan R.; Ruhl, Rebecca; Tsikitis, Vassiliki; Vaccaro, Gina; Wong, Melissa; Mayo, Skye.

In: CMGH Cellular and Molecular Gastroenterology and Hepatology, Vol. 3, No. 2, 01.03.2017, p. 163-173.

Research output: Contribution to journalReview article

Zarour, Luai R. ; Anand, Sudarshan ; Billingsley, Kevin ; Bisson, William H. ; Cercek, Andrea ; Clarke, Michael F. ; Coussens, Lisa ; Gast, Charles E. ; Geltzeiler, Cristina B. ; Hansen, Lissi ; Kelley, Katherine A. ; Lopez, Charles ; Rana, Shushan R. ; Ruhl, Rebecca ; Tsikitis, Vassiliki ; Vaccaro, Gina ; Wong, Melissa ; Mayo, Skye. / Colorectal Cancer Liver Metastasis : Evolving Paradigms and Future Directions. In: CMGH Cellular and Molecular Gastroenterology and Hepatology. 2017 ; Vol. 3, No. 2. pp. 163-173.
@article{417bb3d848684bba9d00c3ff830c39d6,
title = "Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions",
abstract = "In patients with colorectal cancer (CRC) that metastasizes to the liver, there are several key goals for improving outcomes including early detection, effective prognostic indicators of treatment response, and accurate identification of patients at high risk for recurrence. Although new therapeutic regimens developed over the past decade have increased survival, there is substantial room for improvement in selecting targeted treatment regimens for the patients who will derive the most benefit. Recently, there have been exciting developments in identifying high-risk patient cohorts, refinements in the understanding of systemic vs localized drug delivery to metastatic niches, liquid biomarker development, and dramatic advances in tumor immune therapy, all of which promise new and innovative approaches to tackling the problem of detecting and treating the metastatic spread of CRC to the liver. Our multidisciplinary group held a state-of-the-science symposium this past year to review advances in this rapidly evolving field. Herein, we present a discussion around the issues facing treatment of patients with CRC liver metastases, including the relationship of discrete gene signatures with prognosis. We also discuss the latest advances to maximize regional and systemic therapies aimed at decreasing intrahepatic recurrence, review recent insights into the tumor microenvironment, and summarize advances in noninvasive multimodal biomarkers for early detection of primary and recurrent disease. As we continue to advance clinically and technologically in the field of colorectal tumor biology, our goal should be continued refinement of predictive and prognostic studies to decrease recurrence after curative resection and minimize treatment toxicity to patients through a tailored multidisciplinary approach to cancer care.",
keywords = "Biomarkers, Colorectal Cancer Liver Metastasis, Hepatic Arterial Infusion, High-Risk Colorectal Cancer, Recurrence",
author = "Zarour, {Luai R.} and Sudarshan Anand and Kevin Billingsley and Bisson, {William H.} and Andrea Cercek and Clarke, {Michael F.} and Lisa Coussens and Gast, {Charles E.} and Geltzeiler, {Cristina B.} and Lissi Hansen and Kelley, {Katherine A.} and Charles Lopez and Rana, {Shushan R.} and Rebecca Ruhl and Vassiliki Tsikitis and Gina Vaccaro and Melissa Wong and Skye Mayo",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.jcmgh.2017.01.006",
language = "English (US)",
volume = "3",
pages = "163--173",
journal = "Cellular and Molecular Gastroenterology and Hepatology",
issn = "2352-345X",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Colorectal Cancer Liver Metastasis

T2 - Evolving Paradigms and Future Directions

AU - Zarour, Luai R.

AU - Anand, Sudarshan

AU - Billingsley, Kevin

AU - Bisson, William H.

AU - Cercek, Andrea

AU - Clarke, Michael F.

AU - Coussens, Lisa

AU - Gast, Charles E.

AU - Geltzeiler, Cristina B.

AU - Hansen, Lissi

AU - Kelley, Katherine A.

AU - Lopez, Charles

AU - Rana, Shushan R.

AU - Ruhl, Rebecca

AU - Tsikitis, Vassiliki

AU - Vaccaro, Gina

AU - Wong, Melissa

AU - Mayo, Skye

PY - 2017/3/1

Y1 - 2017/3/1

N2 - In patients with colorectal cancer (CRC) that metastasizes to the liver, there are several key goals for improving outcomes including early detection, effective prognostic indicators of treatment response, and accurate identification of patients at high risk for recurrence. Although new therapeutic regimens developed over the past decade have increased survival, there is substantial room for improvement in selecting targeted treatment regimens for the patients who will derive the most benefit. Recently, there have been exciting developments in identifying high-risk patient cohorts, refinements in the understanding of systemic vs localized drug delivery to metastatic niches, liquid biomarker development, and dramatic advances in tumor immune therapy, all of which promise new and innovative approaches to tackling the problem of detecting and treating the metastatic spread of CRC to the liver. Our multidisciplinary group held a state-of-the-science symposium this past year to review advances in this rapidly evolving field. Herein, we present a discussion around the issues facing treatment of patients with CRC liver metastases, including the relationship of discrete gene signatures with prognosis. We also discuss the latest advances to maximize regional and systemic therapies aimed at decreasing intrahepatic recurrence, review recent insights into the tumor microenvironment, and summarize advances in noninvasive multimodal biomarkers for early detection of primary and recurrent disease. As we continue to advance clinically and technologically in the field of colorectal tumor biology, our goal should be continued refinement of predictive and prognostic studies to decrease recurrence after curative resection and minimize treatment toxicity to patients through a tailored multidisciplinary approach to cancer care.

AB - In patients with colorectal cancer (CRC) that metastasizes to the liver, there are several key goals for improving outcomes including early detection, effective prognostic indicators of treatment response, and accurate identification of patients at high risk for recurrence. Although new therapeutic regimens developed over the past decade have increased survival, there is substantial room for improvement in selecting targeted treatment regimens for the patients who will derive the most benefit. Recently, there have been exciting developments in identifying high-risk patient cohorts, refinements in the understanding of systemic vs localized drug delivery to metastatic niches, liquid biomarker development, and dramatic advances in tumor immune therapy, all of which promise new and innovative approaches to tackling the problem of detecting and treating the metastatic spread of CRC to the liver. Our multidisciplinary group held a state-of-the-science symposium this past year to review advances in this rapidly evolving field. Herein, we present a discussion around the issues facing treatment of patients with CRC liver metastases, including the relationship of discrete gene signatures with prognosis. We also discuss the latest advances to maximize regional and systemic therapies aimed at decreasing intrahepatic recurrence, review recent insights into the tumor microenvironment, and summarize advances in noninvasive multimodal biomarkers for early detection of primary and recurrent disease. As we continue to advance clinically and technologically in the field of colorectal tumor biology, our goal should be continued refinement of predictive and prognostic studies to decrease recurrence after curative resection and minimize treatment toxicity to patients through a tailored multidisciplinary approach to cancer care.

KW - Biomarkers

KW - Colorectal Cancer Liver Metastasis

KW - Hepatic Arterial Infusion

KW - High-Risk Colorectal Cancer

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=85014082003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014082003&partnerID=8YFLogxK

U2 - 10.1016/j.jcmgh.2017.01.006

DO - 10.1016/j.jcmgh.2017.01.006

M3 - Review article

VL - 3

SP - 163

EP - 173

JO - Cellular and Molecular Gastroenterology and Hepatology

JF - Cellular and Molecular Gastroenterology and Hepatology

SN - 2352-345X

IS - 2

ER -